Important note: Information in this article was accurate in August 2004. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - Vol. 5, No. 7, August/September 2004
Simon Collins, HIV i-Base
A South African study from Geel and colleagues reported the new data on the potential effect of fluconazole to increase nevirapine plasma levels.
In a single-centre, open-label, single-arm trial the pharmacokinetic parameters of fluconazole were measured alone and in combination with nevirapine in 24 patients on a stable regimen of three nucleoside analogue antiretrovirals.
The nevirapine effect on fluconazole pharmacokinetic parameters was minimal. However, the clearance of nevirapine was halved during concomitant administration of fluconazole resulting in an approximate doubling of nevirapine Cmin, Cmax and AUC.
95% of drug-related adverse events occurred during the period of co-administration of nevirapine and fluconazole.
During this phase 25% (CI 7-43%) of patients developed serious hepatotoxicity including two cases of clinical hepatitis (8.3%) and four cases of transient grade-4 transaminase elevation (16.7%).
The incidence of serious hepatotoxicity with the combination (25.0%) was much higher than reported in other studies using nevirapine alone (8.8%).
The authors concluded that because of pharmacokinetic interaction and the apparent increased incidence of toxicity, the combination of nevirapine and fluconazole should be used with caution.
Reference: Geel J, Pitt J, Orrell CJ et al. The effect of fluconazole on nevirapine pharmacokinetics. Int Conf AIDS. 2004 Jul 11-16;15:Abstract No. TuPeB4606.
Comment
These results need to be confirmed. This study lacked an interpatient comparison, and only compared treated patients with historical controls of nevirapine used without fluconazole, who are likely to have different patient characteristics.
If both drugs are used together, additional monitoring for nevirapine toxicity should be included.
Itraconazole may be a safer option for treating non-CNS fungal infections and perhaps should be the agent of choice for non-invasive candidiasis in patients on nevaripine.
040810
IB040507-13
©2004. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
